Inflammatory Arthritis

Session Debate: Guidelines are useful in psoriatic arthritis or are they?
Pro: Arthur Kavanaugh, USA
Con: Peter Nash, Australia
Session Round Table: Non-radiographic ankylosing spondylitis
Epidemiology, prevalence and diagnosis
Arthur Kavanaugh, USA
Management and progression/prognosis
Session Debate: Biologic choice in psoriatic arthritis/spondylarthropathies
If not anti-IL-17, how do the alternatives stack up?
Matt Brown,  Australia
IL17 blockade should be the first choice in PSA/AS
Peter Nash, Australia
Session Round Table: What are the best ways to assess therapies?
Randomised trials
Mark Genovese, USA
Database studies
Denis Choquette, Canada
Australian initiatives for Cochrane and clinical trials
Rachelle Buchbinder, Australia
Session Debate: Management of comorbidities in inflammatory arthritis
It is the responsibility of the family physician
Kevin Pile, Australia
Rheumatologists should take the lead
Boulos Haraoui, Canada
Session Lecture: Dose adjustments in inflammatory arthritis
Rheumatoid arthritis
Tsutomu Takeuchi, Japan
Ankylosing spondylitis/psoriatic arthritis
Paul Bird, Australia
Session Round Table: Patient reported outcomes
Patients reported outcomes value add to rheumatology practice
Denis Choquette, Canada
Role of nurse practitioner
Emma Bavage, Australia
Practical application in daily practice
Kathleen Tymms, Australia
Session Round Table: First treatment choice in difficult rheumatoid arthritis
Mark Genovese, USA
Injection therapy
Boulos Haraoui, Canada
Session Lecture: Practical approach to the extra-articular manifestations of rheumatoid arthritis
Interstitial lung disease
Tsutomu Takeuchi, Japan
Maureen Rischmeuller, Australia
Stephen Hall, Australia
Session Lecture/Round Table: Seronegative rheumatoid arthritis
Is sero-negative rheumatoid arthritis a different entity: Epidemiology, clinical features?
Tore K. Kvien, Norway
Prognosis and management
Susanna M. Proudman, Australia